Alzheimer’s Association International Conference 2025 (AAIC 2025)
Toronto, Ontario, Canada 27 July 2025 - 31 July 2025
Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
byAudrey Abella
Findings from the phase IIb/III ATTENTION-AD study reflect the continued benefit of oral blarcamesine in individuals with early Alzheimer’s disease (AD) after receiving the drug continuously for up to 4 years.
Oral blarcamesine delivers long-term benefit in early AD
24 Oct 2025
TRAILBLAZER-ALZ 6 updates support new donanemab dosing schedule for AD
10 Oct 2025
byAudrey Abella
In the 18-month results from the phase IIIb TRAILBLAZER-ALZ 6 trial, the newly recommended dosing schedule of donanemab results in a significant reduction in the incidence of amyloid-related imaging abnormalities with effusion/oedema (ARIA-E) compared with standard dosing in adults with early symptomatic Alzheimer’s disease (AD).